Monopar Therapeutics Inc. (MNPR) — Stock Score Summary

Monopar Therapeutics Inc. (MNPR) has a MoatMap StockRank of 16/100 based on Quality (48/100), Value (28/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. Monopar Therapeutics is a clinical-stage oncology biotech. It has no commercialized products, no revenues, and high cash burn. It fails our quality compounder filter and does not fit into our CDMO pricing power theme as it is a drug developer, not a manufacturer.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe cancers. Its proprietary drug candidates target mechanisms that address chemotherapy-induced toxicities and resistance, alongside novel anti-cancer agents. Monopar operates as a niche player in oncology, aiming to improve outcomes for patients with difficult-to-treat cancers and significant unmet medical needs.

Key Financial Metrics

Price$60.63
Market Cap$432M
P/E (Forward)-18.84
Price/Book2.89
Return on Equity-15.9%
Return on Invested Capital-12.1%
Debt/Equity0.17
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-5M

Monopar Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Monopar Therapeutics Inc.’s (MNPR) StockRank?
MoatMap’s StockRank for Monopar Therapeutics Inc. (MNPR) is 16/100, with a Strong Sell signal. It is a composite of Quality (48), Value (28), and Momentum (25) factor ranks across MoatMap’s 19,000+ stock universe.
Does Monopar Therapeutics Inc. have an economic moat?
Monopar Therapeutics Inc. (MNPR) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Monopar Therapeutics Inc. a buy, hold, or sell?
MoatMap’s current signal for Monopar Therapeutics Inc. (MNPR) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Monopar Therapeutics Inc. in?
Monopar Therapeutics Inc. (MNPR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksMNPR deep dive reportAI ChampionsHow we score stocksSense-check another stock